| Document |
Document Title |
|
WO/2020/011086A1 |
Involved are a class of benzodiazepine heterocyclic compounds, a preparation method therefor and the use thereof, as well as a pharmaceutical composition containing the compound. In particular, the present invention relates to the compou...
|
|
WO/2020/011020A1 |
A mefatinib composition, related compounds, a preparation method therefor and use thereof. The mefatinib composition comprises mefatinib represented by formula (I) and a compound represented by formula (II) having a normalized percentage...
|
|
WO/2020/014332A1 |
The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as ...
|
|
WO/2020/013500A1 |
The present invention relates to a uracil-based compound or a pesticidally acceptable salt thereof, and an herbicidal composition comprising same, the herbicidal composition comprising the uracil-based compound and/or the pesticidally ac...
|
|
WO/2020/011220A1 |
A heteroaryl derivative represented by general formula (I), a preparation method therefor, and a pharmaceutical composition comprising the derivative and a use thereof as a therapeutic agent, in particular as an A2a receptor and/or an A2...
|
|
WO/2020/006869A1 |
The present invention relates to the technical field of pesticides, and particularly relates to a substituted pyrimidinyl formyl oxime derivative represented by general formula I, a preparation method therefor, a herbicidal composition a...
|
|
WO/2020/010090A1 |
The present invention includes novel compositions and methods for treating comprising a compound with the Formula I: where n = 0-5; X = NH, O, S, CH2; Y = Phenyl, a phenyl group substituted with at least one methyl, a phenyl group substi...
|
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2020/001448A1 |
The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infecti...
|
|
WO/2020/006341A1 |
The present invention relates to (S)-3-(2-(4-(benzyl)-3-oxopiperazin-l- yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating e.g. cardiovascular, kidney, li...
|
|
WO/2019/245878A1 |
Heterocyclic compounds are provided. In particular, the heteroatom of the heterocyclic compound may be nitrogen. The heterocyclic compounds may demonstrate capacity of stabilizing photoactive compounds. Topical compositions comprising th...
|
|
WO/2019/245877A1 |
Heterocyclic compounds are provided. In particular, the heteroatom of the heterocyclic compound may be nitrogen. The heterocyclic compounds may demonstrate capacity of stabilizing photoactive compounds. Topical compositions comprising th...
|
|
WO/2019/246422A1 |
Described herein are methods for inhibiting generation of one or more non-classical variant(s) of amyloid precursor protein (APP) gene. Provided herein are methods for diagnosing an individual having or suspected of having Alzheimer's- d...
|
|
WO/2019/246109A1 |
Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions.
|
|
WO/2019/246343A1 |
The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a ...
|
|
WO/2019/242689A1 |
Provided is a compound as shown in formula (I), an isomer thereof, hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, and prodrug thereof, and a preparation method and use of same in the preparation of a drug as ...
|
|
WO/2019/241141A1 |
The invention provides methods of inhibiting myocardial injury in a subject which comprises administering a PDE1 or PDE1C inhibitor to the subject in an effective amount so as to inhibit myocardial injury in the subject. In accordance wi...
|
|
WO/2019/241715A1 |
The application relates to a compound having Formula I which modulates the activity of HER2 and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and...
|
|
WO/2019/238970A1 |
The present invention relates to sphingolipids, and more particularly to a method for the production of sphingoid bases, especially sphingosine, and novel derivatives thereof. The sphingoid bases are herein produced by making use of a vi...
|
|
WO/2019/238427A1 |
The present invention relates to one crystalline form A of ethyl 2-[2-[2-chloro-4-fluoro-5-[3-methyl- 2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]phenoxy]
acetate, a process for the production of this crystalline form, formulatio...
|
|
WO/2019/233459A1 |
Provided are a quinoline or quinazoline derivative having a structure of formula (I), a pharmaceutical composition comprising the compound of formula (I), and use of the compound in the preparation of a medicament for preventing or treat...
|
|
WO/2019/236487A1 |
The present invention provides a class of pyrimidinedione cyclohekenyl compounds and methods of using these compounds as glucocorticoid receptor modulators.
|
|
WO/2019/233862A1 |
The invention relates to substituted phenylpyrimidines of general formula (I), to their agrochemically acceptable salts (I), and to the use thereof in the field of plant protection.
|
|
WO/2019/236496A1 |
The present disclosure relates to a class of pyrimidine derivatives of formula (I) having immunomodulating properties that act via TLR7 which are useful in the treatment of lung cancer and other respiratory conditions.
|
|
WO/2019/229250A1 |
The invention relates to a compound of the formula (I) as novel inhibitorof N- acylphosphatidylethanolamine phospholipase D (NAPE-PLD), and to use thereof for the prophylaxis ortreatment ofdiseases associated with NAPE-PLD. (I) wherein i...
|
|
WO/2019/227771A1 |
Disclosed are a substituted pyrimidine-4-formic acid derivative and an herbicidal composition thereof. The pyrimidine-4-formic acid derivative and the herbicidal composition thereof have excellent herbicidal activity and crop selectivity.
|
|
WO/2019/224754A1 |
Peptides, peptidomimetics and small molecules, collectively referred to as "decoy peptides", are provided, which interfere with binding to a TIR domain of a toll-like receptor 4 (TLR4), and inhibit a TLR4-induced signaling pathway. These...
|
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
|
WO/2019/218998A1 |
The present invention relates to an acrylate compound represented by formula I and a use thereof in the preparation of a drug used for the prevention or treatment of diseases or conditions associated with IL-17F.
|
|
WO/2019/219771A1 |
There is provided a process for the preparation of a compound of formula I, wherein R1 and R2 each have the meanings provided in the description. There is also provided a process for the preparation of pharmaceutically-active compounds c...
|
|
WO/2019/218024A1 |
The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compoun...
|
|
WO/2019/214610A1 |
Provided herein are dihydropyrimidine derivatives which are useful in the treatment of HBV infection or HBV-induced diseases, as well as pharmaceutical or medical applications thereof.
|
|
WO/2019/213606A2 |
Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms cerdulatinib and salts or co-crystals thereof.
|
|
WO/2019/213006A1 |
Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other condition...
|
|
WO/2019/213545A1 |
The present disclosure provides processes for the preparation of cerdulatinib, which is of formula (I): Formula (I) or a salt thereof. The disclosure also provides intermediates and processes for the preparation of the intermediates usef...
|
|
WO/2019/213570A1 |
Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian ...
|
|
WO/2019/208599A1 |
The present invention provides a compound having an excellent controlling effect on harmful arthropods. A compound represented by formula (I) has an excellent controlling effect on harmful arthropods.
|
|
WO/2019/208598A1 |
The present invention provides a compound having an excellent controlling effect on harmful arthropods. A compound represented by formula (I) (in the formula, R represents a methyl group or an ethyl group) has an excellent controlling ef...
|
|
WO/2019/209738A1 |
The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to ph...
|
|
WO/2019/201621A1 |
The present invention relates to a compound of Formula (I) wherein Ar1 is selected from substituted or unsubstituted C2 to C36heteroaryl and the group Ar1 is bound to the remaining structure represented by Formula (I) via one of its carb...
|
|
WO/2019/199621A1 |
The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are through.macrophage migration inhibitory factor (MIF) or immunoglubin G (I...
|
|
WO/2019/199864A1 |
The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or in...
|
|
WO/2019/200120A1 |
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
|
|
WO/2019/196938A1 |
Related to a quinazoline compound serving as an EFGR triple mutation inhibitor and applications thereof. Specifically, disclosed are a compound as represented by the following formula (I), a pharmaceutical composition comprising the comp...
|
|
WO/2019/199756A1 |
The present invention provides prodrugs and methods of use thereof.
|
|
WO/2019/196838A1 |
Provided in the present invention are pharmaceutically acceptable salts of a compound, N-((5-((5-chloro-4-((naphthalen-2-yl)amino))pyrimidin-2-yl)a
mino)-2-((N-methyl-N- dimethylaminoethyl)amino)-4-methoxyphenyl)acrylamide, especially ph...
|
|
WO/2019/199800A1 |
This invention is in the field of medicinal pharmacology. In particular, the invention relates to a new class of small-molecules having a pyrazino-pyrimidine-dione (or related) structure which function as modulators (activators, inhibito...
|
|
WO/2019/195751A1 |
Compounds of formula (I) wherein, R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as...
|
|
WO/2019/192992A1 |
The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-l,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiet...
|
|
WO/2019/194594A1 |
The present specification relates to a compound represented by formula 1 and an organic electronic device comprising same.
|
